AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CSL LIMITED

181.990

+3.3101.85%

Volume:1.41M

Turnover:253.99M

Market Cap:87.16B

PE:-23.68

High:181.990

Open:178.500

Low:178.010

Close:178.680

52wk High:216.734

52wk Low:88.830

Shares:478.91M

Float Shares:478.91M

Volume Ratio:1.47

T/O Rate:0.29%

Dividend:4.19

Dividend Rate:2.30%

EPS(TTM):-7.685

EPS(LYR):-7.684

ROE:-15.83%

ROA:7.26%

PB:4.10

PE(LYR):-23.68

Loading ...

Overview Company News Filings

CSL : Agreements Provide CSL with Additional Certainty Regarding Exposure to U.S. Drug Pricing & Certain Section 232 Tariffs

THOMSON REUTERS

CSL : Entered into Onshoring Agreement with the U.S. Department of Commerce

THOMSON REUTERS

CSL : Project to Substantially Increase Co's Ability to Produce Immunoglobulins & Albumin for People with Rare Diseases & Serious Conditions

THOMSON REUTERS

CSL Ltd: Project is Expected to Create at Least 300 New Pharmaceutical Manufacturing Jobs and Approximately 800 Construction and Related Jobs

THOMSON REUTERS

CSL : Does not Anticipate Any Material Impact During Fiscal Year 2027

THOMSON REUTERS

CSL’s latest result suggests the worst may be over

Morning Star AU

Is CSL (ASX:CSL) Cheap On Results, 2027 Guidance And Its Dividend?

Simply Wall St.

CSL (ASX:CSL) Is Up 24.5% After Posting a Net Loss but Guiding for NPAT Growth - What's Changed

Simply Wall St.

Carlisle Companies (CSL) Dividend Hike Puts Its Undervalued Narrative In Focus

Simply Wall St.

Weekly earnings wrap: BHP, CSL, NAB and more

Morning Star AU

ASX healthcare giant rallies despite a fall in profits

Morning Star AU

CSL (ASX:CSL) Reported A Net Loss, Is The Rebound Already Priced In?

Simply Wall St.

Banks Drag Australian Shares Lower; WiseTech Slides Nearly 9%

ASX Midday Sector Update: Healthcare Stocks Jump, Information Technology Sector Struggles

MT Newswires Live

Haemonetics Shares Rise After Signing Supply Agreement With CSL Plasma

MT Newswires Live

Asia Morning Call-Global Markets

Haemonetics Signs Non-Exclusive US Plasma Supply Deal with CSL Plasma for NexSys PCS Devices, Disposables

CSL (ASX:CSL) Shares Confront Profit Reversal As Recovery Case Stays Unproven

Simply Wall St.

Switzerland's Basilea H1 Revenue Rises on Cresemba Demand; Ups 2026 Profit Outlook

CSL Expects Flat Revenue for Fiscal 2027 With Return to Profit Growth

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/CSL.AU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":181.99,"timestamp":1791349920000,"preClose":178.68,"halted":0,"volume":1408941,"delay":0,"changeRate":0.018524736959928376,"nameEN":"CSL LIMITED","floatShares":478911979,"shares":478911979,"eps":-7.685473724124856,"marketStatus":"Not Yet Opened","change":3.31,"latestTime":"10-07 16:12:00 AEDT","open":178.5,"high":181.99,"low":178.01,"amount":253991643,"amplitude":0.022274,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.685473724124856,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791414000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":178.68,"dividendRate":0.022371,"openAndCloseTimeList":[[1791327600000,1791349200000]],"volumeRatio":1.4691211990918183,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":181.99,"auctionPrice":182,"auctionVolume":1758,"auctionTime":1791405133346,"referenceTime":1791369003092,"auction":1,"marketStatus":"盘前竞价","timestamp":1791405133346}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":478911979,"roa":"7.26%","roe":"-15.83%","lyrEps":-7.684264,"volumeRatio":1.4691211990918183,"shares":478911979,"dividePrice":4.194028,"high":181.99,"amplitude":0.022274,"preClose":178.68,"low":178.01,"week52Low":88.83,"pbRate":"4.10","psRate":"3.84","week52High":216.734,"institutionHeld":0,"latestPrice":181.99,"eps":-7.685473724124856,"divideRate":0.023045,"volume":1408941,"delay":0,"ttmEps":-7.685473724124856,"open":178.5,"prevYearClose":168.21,"prevWeekClose":175.35,"prevMonthClose":184.22,"prevQuarterClose":184.22,"fiveDayClose":184.22,"twentyDayClose":171.21,"sixtyDayClose":120.175,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":5,"dividendGrowthRate":0.003543182641490467,"fiveYearAvgDividendRate":0.01866467227077263},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2026-08-18","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-10","defaultRemindTime":1788912000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-02","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1788876000000,"payDate":"2026-10-02"},{"date":"2026-08-18","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664082000","title":"CSL : Agreements Provide CSL with Additional Certainty Regarding Exposure to U.S. Drug Pricing & Certain Section 232 Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2664082000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664082000?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:22","pubTimestamp":1788204143,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0J9:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","CSL.AU","BK7511","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664007000","title":"CSL : Entered into Onshoring Agreement with the U.S. Department of Commerce","url":"https://stock-news.laohu8.com/highlight/detail?id=2664007000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664007000?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:22","pubTimestamp":1788204143,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0J9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7067","CSL.AU","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664000920","title":"CSL : Project to Substantially Increase Co's Ability to Produce Immunoglobulins & Albumin for People with Rare Diseases & Serious Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000920","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664000920?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:22","pubTimestamp":1788204143,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0J9:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7511","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664000707","title":"CSL Ltd: Project is Expected to Create at Least 300 New Pharmaceutical Manufacturing Jobs and Approximately 800 Construction and Related Jobs","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664000707?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:22","pubTimestamp":1788204143,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0J9:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CSL.AU","BK7511","BK7508","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664000088","title":"CSL : Does not Anticipate Any Material Impact During Fiscal Year 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2664000088","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664000088?lang=en_us&edition=fundamental","pubTime":"2026-09-01 03:22","pubTimestamp":1788204143,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0J9:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7511","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664800678","title":"CSL’s latest result suggests the worst may be over","url":"https://stock-news.laohu8.com/highlight/detail?id=2664800678","media":"Morning Star AU","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664800678?lang=en_us&edition=fundamental","pubTime":"2026-08-31 00:00","pubTimestamp":1788105600,"startTime":"0","endTime":"0","summary":"CSL’s (ASX:CSL) earnings result was not particularly impressive on the surface. Underlying earnings fell 2%, while a USD 7.1 billion impairment charge pushed statutory earnings into the red. Despite t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/stocks/csls-latest-result-suggests-worst-may-be-over","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/stocks/csls-latest-result-suggests-worst-may-be-over","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["CDIG","GXDW","PMDE","JOYT","VGFPF","RGLO","BK7508","FEBU","BK7067","BK7511","BK7501","DECU","CSL.AU","VOTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662032654","title":"Is CSL (ASX:CSL) Cheap On Results, 2027 Guidance And Its Dividend?","url":"https://stock-news.laohu8.com/highlight/detail?id=2662032654","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662032654?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:21","pubTimestamp":1787865674,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) is in focus after releasing its full year 2026 results, issuing earnings guidance for 2027, and declaring a US$1.62 per share dividend. This combination gives investors several fresh data points to assess.\nThe CSL share price has reacted sharply around these results, with a 30 day share price return of 45.48% and a 90 day share price return of 79.98% taking it to A$173.88, even though the 1 year total shareholder return is still down 16.24% and the 5 year total shareholder...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/is-csl-asxcsl-cheap-on-results-2027-guidance-and-its-dividen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/is-csl-asxcsl-cheap-on-results-2027-guidance-and-its-dividen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSL.AU","BK7067","BK7501","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661925792","title":"CSL (ASX:CSL) Is Up 24.5% After Posting a Net Loss but Guiding for NPAT Growth - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2661925792","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661925792?lang=en_us&edition=fundamental","pubTime":"2026-08-21 10:28","pubTimestamp":1787279328,"startTime":"0","endTime":"0","summary":"In August 2026, CSL Limited reported full-year results showing revenue rising slightly to US$15.80 billion but moving from prior net income to a US$2.58 billion net loss, while also declaring a US$1.62 per share dividend for the six months ended June 30, 2026, payable on October 2, 2026.\nAt the same time, CSL issued 2027 guidance calling for revenue to remain in line with the prior year but underlying NPAT to increase by about 5%, highlighting a contrast between current headline losses and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-is-up-245-after-posting-a-net-loss-but-guiding-fo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-is-up-245-after-posting-a-net-loss-but-guiding-fo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSL","LU1169589451.USD","BK7067","AGIX","QTOC","LU0728928796.USD","CHAT","LU1169590202.USD","ARTY","BK7501","AIPO","SGXZ23171101.USD","BK7511","CSL.AU","BK4086","BK7508","VTHR","SG9999004303.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660155477","title":"Carlisle Companies (CSL) Dividend Hike Puts Its Undervalued Narrative In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2660155477","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660155477?lang=en_us&edition=fundamental","pubTime":"2026-08-20 09:38","pubTimestamp":1787189919,"startTime":"0","endTime":"0","summary":"Dividend increase draws attention to Carlisle Companies stock\nCarlisle Companies (CSL) has drawn investor focus after its board approved a 14% increase in the regular quarterly dividend to $1.25 per share, payable on September 1, 2026.\nSee our latest analysis for Carlisle Companies.\nCarlisle Companies’ dividend move comes after a period where the share price has shown positive momentum in recent months, with an 11.7% 1 month share price return and a 10.0% 3 month share price return, while the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/carlisle-companies-csl-dividend-hike-puts-its-undervalued-na","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/carlisle-companies-csl-dividend-hike-puts-its-undervalued-na","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSL.AU","BK7508","LU0728928796.USD","BK7067","LU1169589451.USD","BK7501","BK4086","SGXZ23171101.USD","CSL","SG9999004303.SGD","BK7511","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661254530","title":"Weekly earnings wrap: BHP, CSL, NAB and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2661254530","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661254530?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:00","pubTimestamp":1787155200,"startTime":"0","endTime":"0","summary":"This is the third edition of our weekly wrap for the August 2026 earnings season. Earnings is now in full swing with some of the largest names on the ASX reporting this week. BHP reported strongly on ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/stocks/weekly-earnings-wrap-bhp-csl-nab-more","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/stocks/weekly-earnings-wrap-bhp-csl-nab-more","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["RGLO","JOYT","GXDW","VOTE","CSL.AU","PMDE","CSL","DECU","BHP.AU","BHP","VGFPF","FEBU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660470729","title":"ASX healthcare giant rallies despite a fall in profits","url":"https://stock-news.laohu8.com/highlight/detail?id=2660470729","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660470729?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:00","pubTimestamp":1787155200,"startTime":"0","endTime":"0","summary":"CSL’s (ASX.CSL) fiscal 2026 underlying earnings fell 2%, in line with the guidance reset in May, and USD 7.1 billion of impairments drove a statutory loss. Fiscal 2027 guidance is for flat revenue and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/stocks/asx-healthcare-giant-rallies-despite-fall-profits","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/stocks/asx-healthcare-giant-rallies-despite-fall-profits","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["BK4585","CSL.AU","BK7508","BK7501","BK7511","IXJ","BK4550","CGCV","VHT","BK4588","NOBL","BK7067","TCAF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660426238","title":"CSL (ASX:CSL) Reported A Net Loss, Is The Rebound Already Priced In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660426238","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660426238?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:32","pubTimestamp":1787146321,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) is in focus after its latest full year results showed sales and revenue near prior levels, a swing to a net loss, fresh 2027 earnings guidance, and a declared dividend.\nSee our latest analysis for CSL.\nThe earnings announcement, new 2027 guidance and dividend decision have triggered a sharp reassessment of CSL, with a 1-day share price return of 17.25% and a 90-day share price return of 60.27%, even though the 1-year total shareholder return is down 28.29% and the 5-year total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-reported-a-net-loss-is-the-rebound-already-priced","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-reported-a-net-loss-is-the-rebound-already-priced","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SG9999004303.SGD","LU1169589451.USD","CSL.AU","CSL","LU1169590202.USD","BK4086","SGXZ23171101.USD","LU0728928796.USD","BK7511","BK7508","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660410952","title":"Banks Drag Australian Shares Lower; WiseTech Slides Nearly 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660410952","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660410952?lang=en_us&edition=fundamental","pubTime":"2026-08-19 15:02","pubTimestamp":1787122979,"startTime":"0","endTime":"0","summary":"Banks drag Australian shares lower; WiseTech slides nearly 9%Aug 19 (Reuters)-Australian shares ended lower on Wednesday as index heavyweight banks extended falls on concerns over mortgage demand, whi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL4N44G0E0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AN3PL.AU","BK7135","BK7142","CBA.AU","BK7507","BK7511","CSL.AU","ANZ.AU","BK7501","BK7503","STO.AU","WTC.AU","BK7067","BK7508","BK7016"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660419637","title":"ASX Midday Sector Update: Healthcare Stocks Jump, Information Technology Sector Struggles","url":"https://stock-news.laohu8.com/highlight/detail?id=2660419637","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660419637?lang=en_us&edition=fundamental","pubTime":"2026-08-19 10:52","pubTimestamp":1787107958,"startTime":"0","endTime":"0","summary":"Healthcare stocks advanced nearly 2% at midday Wednesday.CSL (ASX:CSL) gained almost 4% in recent trade.On the flip side, the information technology sector struggled, shedding almost 5%.Wisetech Global (ASX:WTC) shares fell nearly 13% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7501","III","BK7511","XBI","BK7503","LU0128526141.USD","BK7067","BK4581","BK4137","WTC.AU","LABU","BK7016","XLV","CSL.AU","LU0029874061.USD","BK4134","BK4588","HCSG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660149195","title":"Haemonetics Shares Rise After Signing Supply Agreement With CSL Plasma","url":"https://stock-news.laohu8.com/highlight/detail?id=2660149195","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660149195?lang=en_us&edition=fundamental","pubTime":"2026-08-19 02:40","pubTimestamp":1787078411,"startTime":"0","endTime":"0","summary":"Haemonetics  shares were up more than 17% in afternoon trading on Tuesday after the company said it entered into a supply agreement with CSL Plasma last week.The deal involves Haemonetics' NexSys PCS plasma collection system with Persona Plus Technology, an automated cell separator system, along with related disposables in the US, according to a Tuesday filing.CSL is expected to transition a portion of its US plasma collection centers to Haemonetics' devices and disposables, but the scope and timing of the implementation are still to be determined, the company said.Price: 105.99, Change: +15.72, Percent Change: +17.41","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999004303.SGD","CSL.AU","SGXZ23171101.USD","BK4086","IE00BLDYK493.USD","CSL","BK7511","LU0106261612.USD","LU1169590202.USD","BK7067","IE00B64QTZ34.USD","BK7501","BK4198","BK7508","LU0205194284.USD","IE0034390439.USD","HAE","LU0205193047.USD","IE00B19Z6F94.USD","LU1169589451.USD","LU0728928796.USD","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660916144","title":"Asia Morning Call-Global Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2660916144","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660916144?lang=en_us&edition=fundamental","pubTime":"2026-08-19 02:39","pubTimestamp":1787078393,"startTime":"0","endTime":"0","summary":"Asia Morning Call-Global MarketsAug 19 (Reuters)-Stock MarketsNet ChngStock MarketsNet ChngS&P/ASX 200**9070.00-3.20NZX 50**13866.18144.20DJIA53377.48-82.30NIKKEI**67460.73-1,759.52Nasdaq26316.48-327.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nL4N44F14G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0511384066.AUD","LU0289960550.SGD","FDIQ","LU0175139822.USD","BK7508","IE00BKPKM429.USD","CSL.AU","BK7067","LU0672654240.SGD","BK4585","LU0289961442.SGD","LU2095319765.USD","LU0109391861.USD","LU1691799644.USD","LU0390134368.USD","LU0289739343.SGD","LU2210149790.SGD","MSCI","LU1267930730.SGD","BK4112","LU0320765059.SGD","LU0708995401.HKD","BK4588","LU2265009873.SGD","BK7511","BK7501","LU1804176565.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660466734","title":"Haemonetics Signs Non-Exclusive US Plasma Supply Deal with CSL Plasma for NexSys PCS Devices, Disposables","url":"https://stock-news.laohu8.com/highlight/detail?id=2660466734","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660466734?lang=en_us&edition=fundamental","pubTime":"2026-08-18 18:06","pubTimestamp":1787047565,"startTime":"0","endTime":"0","summary":"Haemonetics signs non-exclusive US plasma supply deal with CSL Plasma for NexSys PCS devices, disposablesHaemonetics signed a non-exclusive U.S. supply agreement with CSL Plasma on Aug. 14, 2026 for N","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLpVv5B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IE00BLDYK493.USD","LU0012050646.USD","IE00B64QTZ34.USD","BK7067","IE0034390439.USD","LU0106261612.USD","BK4198","LU1169590202.USD","LU1169589451.USD","HAE","LU0205193047.USD","IE00B19Z6F94.USD","LU0205194284.USD","BK7511","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660466219","title":"CSL (ASX:CSL) Shares Confront Profit Reversal As Recovery Case Stays Unproven","url":"https://stock-news.laohu8.com/highlight/detail?id=2660466219","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660466219?lang=en_us&edition=fundamental","pubTime":"2026-08-18 17:22","pubTimestamp":1787044958,"startTime":"0","endTime":"0","summary":"CSL stock went into this result having climbed over the past quarter, closing at A$157.82, yet the latest numbers land with a jolt. The global biotech giant posted a trailing twelve month loss from continuing operations of US$2.99b on revenue of US$15.80b. That kind of earnings squeeze grabs short term traders by the throat. For long term investors, the real question now is how to weigh that loss against analyst forecasts that point to a return to profitability, as well as the current gap...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-shares-confront-profit-reversal-as-recovery-case","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-shares-confront-profit-reversal-as-recovery-case","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SG9999004303.SGD","SGXZ23171101.USD","GXDW","CSL.AU","BK7067","PMDE","CSL","DECU","FEBU","BK7508","JOYT","BK7511","LU1169589451.USD","VOTE","BK7501","VGFPF","RGLO","BK4086","LU0728928796.USD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660454593","title":"Switzerland's Basilea H1 Revenue Rises on Cresemba Demand; Ups 2026 Profit Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2660454593","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660454593?lang=en_us&edition=fundamental","pubTime":"2026-08-18 13:26","pubTimestamp":1787030795,"startTime":"0","endTime":"0","summary":"Switzerland's Basilea H1 revenue rises on Cresemba demand; ups 2026 profit outlookOverviewSwitzerland biopharma firm's H1 2026 revenue grew 14% yr/yr to CHF 119 mlnOperating profit for H1 2026 rose 32","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nL1N44F03R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","LU1064130708.USD","BK7511","00656","BK1230","002422","LU1934453819.USD","BK7067","LU0196878994.USD","LU1979443071.USD","HK0000320264.USD","02696","HK0000306701.USD","BK0239","BK7501","BK7508","HK0000320223.HKD","HK0000306685.HKD","BK1161","LU2148510915.USD","06990","BK0060","LU1064131003.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660645155","title":"CSL Expects Flat Revenue for Fiscal 2027 With Return to Profit Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2660645155","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660645155?lang=en_us&edition=fundamental","pubTime":"2026-08-18 12:24","pubTimestamp":1787027041,"startTime":"0","endTime":"0","summary":"CSL  expects fiscal 2027 revenue to be flat while making a return to profit growth after fiscal 2026 results beat estimates amid restructuring.The biotechnology company reported $6.43 in underlying NPATA earnings per share for fiscal 2026, compared with $6.65 a year ago and beating analysts' estimates surveyed by FactSet of $6.27.Revenue for the year was $15.8 billion, beating the estimate of $15.38 billion from analysts polled by FactSet, while paying restructuring costs of $799 million.The biotechnology firm attributed the results to \"strong fundamentals\" of the plasma industry and said momentum is building behind its newer therapy products.Looking ahead, CSL expects fiscal 2027 revenue to be flat with 5% growth in its underlying net profit after tax.\"CSL is positioned for a return to sustainable growth, supported by solid plasma market fundamentals, a simplified business and targeted investment in our commercial capabilities and development programs,\" said Interim Chief Executive Of","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CSL.AU","CSL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}